Home >> Professional Blog

Seven Poster Abstracts Highlight MiMedx Allografts

MiMedx Group, Inc. (NASDAQ: MDXG) announced the summaries of a selection of the seven posters highlighting MiMedx allografts presented at the recent 10th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona.

The posters chronicled the clinical effectiveness of the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts and detailed a wide range of wounds and injuries with varying degrees of etiologies. A sampling of the posters presenting dHACM cases and studies, along with a summary of the respective study results and conclusions are as follows:

  • EpiFix Utilization for Advanced Wound Therapy in an Evidence Based Approach to Treat Foot Ulcers.
    • Results: 10 non-healing diabetic foot ulcers (DFUs) and 3 pressure ulcers were treated with EpiFix®. 75% of the ulcers healed with EpiFix® at an average healing time of 11.7 weeks after 3.5 applications. Complete healing occurred in 67% of the DFUs and 100% of pressure ulcers. Of the 3 DFUs not healing 100%, 2 were non-compliant and one had foot deformity issues prior to the study causing discontinuation of the graft.
    • Conclusion: Multiple advantages were noted in using EpiFix® to treat non-healing wounds in the VA clinic setting including ease of use and availability of multiple graft sizes to minimize waste. With adequate wound debridement and proper wound bed maintenance, a 75% healing rate of non-healing foot ulcers was achieved with the utilization of EpiFix®.
  • Dehydrated Human Amnion/Chorion Membrane for the Treatment of Full-Thickness Plantar Burn in a Diabetic Patient: A Case Report.
    • Results: Rapid healing of wound occurred with epithelialization essentially complete 4 weeks after dHACM application.
    • Conclusion: This case report demonstrated that dHACM can be used as an effective treatment for plantar burns in diabetics and deserves further study.
  • Treatment of Lower Extremity Chronic Wounds with Dehydrated Human Amnion/Chorion Membrane (dHACM): A Vascular Compromised Cohort (ABI<.65).
    • Results: Patients with wound chronicity and an abnormally low ankle-brachial index (low blood flow to the limbs) were treated with standard wound treatment prior to initiation of dHACM therapy. Wounds were healed with an average weeks to closure of 7.42 and an average of 4.4 applications.
    • Conclusion: dHACM is an extremely efficacious and cost effective alternative in patients failing to achieve appropriate wound area reduction in a timely manner. In this subset of patients, when compared to the previously utilized advanced wound care modalities, a 75% cost savings was realized.
  • Dehydrated Human Amnion/Chorion Membrane Allograft for the Treatment of a Post Surgical Amputation Wound in a Diabetic Patient.
    • Results: Following sharp debridement period of August 13th through September 2nd to prepare wound for advanced wound healing therapy with EpiFix®, advanced wound healing with EpiFix® started on September 3rd and patient healed on October 15th.
    • Conclusion: Post-surgical patients need aggressive antibiotic treatment for an extended period of time. Aggressive chemical and sharp debridement is necessary to prepare wound bed. Speed to closure, cost effectiveness of multiple sizes and ease of use are positive attributes for EpiFix®.
  • Experience with dHACM for a Complicated Sternal and Abdominal Wound.
    • Results: A total of 6 applications were used over 10 week period; patient presented in week 12 with full closure and wound has continued to be resolved to date.
    • Conclusion: dHACM is a very effective treatment for complicated sternal and abdominal wounds as well as lower extremity ulcerations.

Mr. Pete Petit, Chairman and CEO of MiMedx, said, "The independent study abstracts presented at Desert Foot are further indications of the clinical and cost effectiveness of our dHACM allografts. When a graft achieves wound closure with these metrics, we believe we are best serving the clinical and economic needs of our market. We continue to champion the cause of reducing costs of wound closure, and these abstracts highlight those goals."

Bill Taylor, President and COO of MiMedx, stated, "In the collective body of work forming the basis for the seven MiMedx poster abstracts, the EpiFix® data involved the treatment of 55 patients. In the combined studies, an average number of 3.5 EpiFix® applications were applied to achieve healed ulcers, and the average number of weeks to achieve healing using the MiMedx allografts was 6.8 weeks. These results mirror the impressive results our dHACM allografts have achieved in prior Randomized Controlled Trials, cross over trials and follow-up studies."